Canadian Respiratory Journal / 2019 / Article / Tab 3

Research Article

Prognostic Value of Concomitant Bronchiectasis in Newly Diagnosed Diffuse Panbronchiolitis Patients on a Maintenance Therapy with Macrolides

Table 3

Univariate and multiple Cox regression analyses for predicting the time to exacerbation since beginning of macrolide therapy in newly diagnosed DPB patients.

ParameterUnivariate analysisMultivariate analysis
β valueStandard errorOR (95% CI) valueβ valueStandard errorOR (95% CI) value

Age0.0100.0061.010 (0.999, 1.021)0.083
Female (yes/no)−0.0290.1890.971 (0.670, 1.407)0.876
Smoking (yes/no)0.3500.2211.419 (0.919, 2.190)0.114
Disease duration (year)0.0490.0231.050 (1.004, 1.099)0.034
Chronic sinusitis (yes/no)0.5760.3331.779 (0.927, 3.414)0.083
CHA test (positive/negative)−0.2560.2630.775 (0.462, 1.298)0.332
BMI (kg/m2)−0.1030.0240.902 (0.861, 0.946)<0.001−0.0580.0270.943 (0.859, 0.994)0.028
FEV1 (% pred)−0.0280.0070.972 (0.959, 0.986)<0.001−0.0160.0080.984 (0.969, 1.000)0.045
Pseudomonas aeruginosa culture (positive/negative)0.8940.1972.445 (1.660, 3.601)<0.0010.4440.2191.559 (1.014, 2.359)0.043
Concomitant bronchiectasis (yes/no)0.7520.1992.121 (1.437, 3.131)<0.0010.4350.2141.545 (1.016, 2.349)0.042

BMI: body mass index; CHA: cold hemagglutination; FEV1: forced expiratory volume in 1 second; OR: odds ratio; CI: confidence interval.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.